Biopharmaceuticals Under the Patient Protection and Affordable Care Act: Determining the Appropriate Market and Data Exclusivity Periods.
- Published in:
- Texas Intellectual Property Law Journal, 2013, v. 21, n. 2, p. 213
- By:
- Publication type:
- Article
Works matching United States Innovation and Competition Act
Results: 10
1
2
A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 11, p. 1556, doi. 10.3390/ph16111556
- By:
- Publication type:
- Article
3
Analysis of the BPCIA, the Pre-Approval Patent Resolution Process, Regulatory Exclusivity Periods, and Complementary Rules Affecting Patent Terms.
- Published in:
- BioProcessing Journal, 2012, v. 11, n. 1, p. 11
- By:
- Publication type:
- Article
4
HARD CHOICES.
- Published in:
- Boston Review, 2021, v. 46, n. 3, p. 29
- By:
- Publication type:
- Article
5
A challenging market.
- Published in:
- 2013
- By:
- Publication type:
- Opinion
6
On the interchangeability of biologic drug products.
- Published in:
- Statistics in Medicine, 2013, v. 32, n. 3, p. 434, doi. 10.1002/sim.5569
- By:
- Publication type:
- Article
7
THE HATCH-WAXMAN ACT: A PATH FORWARD FOR MAKING IT MORE MODERN.
- Published in:
- William Mitchell Law Review, 2014, v. 40, n. 4, p. 1200
- By:
- Publication type:
- Article
8
Seeking clarity regarding The BPCIA.
- Published in:
- Journal of Generic Medicines, 2015, v. 12, n. 2, p. 74, doi. 10.1177/1741134315618536
- By:
- Publication type:
- Article
9
Schumer's Anti-China Bill Sacrifices Climate for Empire.
- Published in:
- CounterPunch, 2021, p. 1
- By:
- Publication type:
- Article
10
The U.S. Biosimilar Pathway: Policy Precedes Science.
- Published in:
- Applied Clinical Trials, 2015, v. 24, n. 6/7, p. 40
- By:
- Publication type:
- Article